Cayman 13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1-d4

PGE₁ is produced by the metabolism of dihomo-γ-linolenic acid (DGLA) by the cyclooxygenase pathway. PGE₁ inhibits platelet aggregation (IC₅₀ = 40 nM) and increases vasodilation.^1,213,14-dihydro-16,16-difluoro PGE₁ is a biologically active metabolite of PGE₁, inhibiting platelet aggregation with comparable potency to the parent compound.^3,2 The addition of two electron-withdrawing fluorine atoms, which should stabilize the molecule against hydrolytic cleavage, may be expected to delay degradation in vivo.⁴ 13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro PGE₁-3,3’,4,4’-d₄) contains four deuterium atoms at the 3, 3’, 4, and 4’ positions. It is intended for use as an internal standard for the quantification of 13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E₁ by GC- or LC-mass spectrometry (MS).

WARNING This product is not for human or veterinary use.